Artan Bio Closes $1M Seed Funding Round to Advance its tRNA Platform

The company will use the funding to advance its mutation-specific platform, support IND-enabling preclinical studies, expand raw material manufacturing, and prepare for its first human clinical trials.

Alongside the financing, ARTAN Bio appointed Brian Bodemann as Chief Executive Officer. Bodemann brings deep scientific expertise and broad experience across life science markets, helping connect ARTAN Bio's platform with future clinical applications, and partnerships.

Co-founder Anthony Schwartz, Ph.D., will move from Chief Executive Officer to Chief Operating Officer. In his new role, he will help strengthen the company's operational and scientific leadership as the platform advances into the next phase of development.

Read More:Celea Therapeutics Raises $180M in Financing Series

Nonsense mutations create premature stop signals that prevent cells from producing complete, functional proteins. These mutations are linked to many genetic and age-related diseases. ARTAN Bio's mutation-specific approach aims to correct these defects at their genetic source, with the potential to treat multiple diseases by restoring normal protein function.

"After building CrossBridge Bio through its acquisition by Eli Lilly, my thesis as a CEO, scientist, and company builder is to back science with the potential to become category-defining," said Michael Torres, Ph.D., Co-Founder and Chief Scientific Officer of ARTAN Bio. "That is what I believe ARTAN Bio can be. The platform sits at the intersection of genetics, aging biology, and programmable medicines, with the potential to address disease at the level of the underlying mutation. I am personally investing because I believe the science is differentiated, the opportunity is significant, and the team is ready to move this toward patients."

"Bringing Brian on as CEO positions ARTAN Bio for the clinical, operational, and partnership work ahead," said Anthony Schwartz, Ph.D., Co-Founder and Chief Operating Officer of ARTAN Bio. "My focus as COO will be on disciplined execution as we move from preclinical research toward human studies. The science has reached the point where disciplined translation is the right next step, and this financing gives us the ability to advance that work with urgency and rigor."

"What drew me to ARTAN Bio is that the science is real and the aperture is wide — one programmable mechanism for restoring proteins that nonsense mutations switch off, with relevance across genetic and aging-driven disease," said Brian Bodemann, incoming Chief Executive Officer. "My focus is to translate that platform into the indications and partnerships where it matters most. Michael and Anthony built something differentiated; the work now is to prove what it can become."

About ARTAN Bio

Founded in 2023, ARTAN Bio is a biotechnology company developing mutation specific therapies for genetic and age related diseases caused by nonsense mutations. Its platform uses engineered suppressor systems, delivered through established technologies to restore normal protein function in affected cells.

Read More:Joulent Receives $1.75 Billion Strategic Minority Investment